Olokizumab
Olokizumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. It is known to target interleukin-6.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
19 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 2 | 5 | 4 | — | — | 10 |
| Arthritis | D001168 | HP_0001369 | M05-M14 | 2 | 5 | 4 | — | — | 10 |
| Covid-19 | D000086382 | — | — | — | 2 | 3 | — | 1 | 4 |
| Severe acute respiratory syndrome | D045169 | EFO_0000694 | J12.81 | — | 2 | 2 | — | — | 2 |
| Necrosis | D009336 | — | — | — | — | 1 | — | — | 1 |
| Lung diseases | D008171 | HP_0002088 | J98.4 | — | 1 | 1 | — | — | 1 |
| Interstitial lung diseases | D017563 | HP_0006530 | J84.89 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Crohn disease | D003424 | EFO_0000384 | K50 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | — | — | — | — | 1 | 1 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | — | — | — | 1 | 1 |
| Communicable diseases | D003141 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Olokizumab |
| INN | olokizumab |
| Description | Olokizumab (humanized mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >4CNI:A,H|OLOKIZUMAB HEAVY CHAIN, FAB PORTION
EVQLVESGGGLVQPGGSLRLSCAASGFNFNDYFMNWVRQAPGKGLEWVAQMRNKNYQYGTYYAESLEGRFTISRDDSKNS
LYLQMNSLKTEDTAVYYCARESYYGFTSYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVS
WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVES
>4CNI:B,L|OLOKIZUMAB LIGHT CHAIN, FAB PORTION
DIQMTQSPSSLSASVGDRVTITCQASQDIGISLSWYQQKPGKAPKLLIYNANNLADGVPSRFSGSGSGTDFTLTISSLQP
EDFATYYCLQHNSAPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ
ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
Identifiers
| PDB | 4CNI |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1743050 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | PAI71R1D2W (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
IL6
IL6
Organism
Homo sapiens
Gene name
IL6
Gene synonyms
IFNB2
NCBI Gene ID
Protein name
interleukin-6
Protein synonyms
B-cell differentiation factor, B-cell stimulatory factor 2, BSF-2, CDF, CTL differentiation factor, Hybridoma growth factor, IFN-beta-2, Interferon beta-2, interleukin BSF-2
Uniprot ID
Mouse ortholog
Il6 (16193)
interleukin-6 (P08505)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 388 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use